Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy
Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
This exploratory study aims to assess the efficacy, safety of the experimental treatment
based on a combination of rituximab (RTX), intravenous (IV) cyclophosphamide (CYC), and
corticosteroids (S) administrated at lower cumulative doses (RCP) for the induction of early
remission in subjects with anti-PLA2R antibody-positive primary membranous nephropathy (PMN)
having nephrotic syndrome (NS).